Researcher:
Yumuk, Perran Fulden

Profile Picture
ORCID

Job Title

Other

First Name

Perran Fulden

Last Name

Yumuk

Name

Name Variants

Yumuk, Perran Fulden

Email Address

Birth Date

Filters

2022 - 20235

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.b5578692-6198-4721-8a0f-f384ca0fcf1d

Search Results

Now showing 1 - 6 of 6
  • Placeholder
    PublicationMetadata only
    Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: a real-life data of Turkish Oncology Group
    (Lippincott Williams and Wilkins (LWW), 2022) Gurbuz, Mustafa; Kilickap, Saadettin; Bilici, Ahmet; Karadurmus, Nuri; Sezer, Ahmet; Sendur, Mehmet Ali Nahit; Paydas, Semra; Artac, Mehmet; Gursoy, Pinar; Uysal, Mukremin; Senol Coskun, Hasan; Tatli, Ali Murat; Disel, Umut; Koksoy, Elif Berna; Guven, Deniz Can; Ugrakli, Muzaffer; Akkus, Erman; Yucel, Sebnem; Erol, Cihan; Karakaya, Serdar; Sakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazik, Ahmet; N/A; Yumuk, Perran Fulden; Selçukbiricik, Fatih; Other; Faculty Member; School of Medicine; School of Medicine; Koç University Hospital; N/A; 202015
    Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n = 33) and 46.8% (n = 29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P = .217). Median PFS was significantly longer in patients who have never smoked (P = .040), have good performance score (P < .001), and responded to the treatment (P < .001). OS was significantly longer in patients with MET mutation (25.6 months, 95% CI: 15.9-35.3) compared to the patients with MET amplification (11.0 months; 95% CI: 5.2-16.8) (P = .049). In never-smokers, median OS was longer than smoker patients (25.6 months [95% CI: 11.8-39.3] vs 16.5 months [95% CI: 9.3-23.6]; P = .049). The most common adverse effects were fatigue (50%), peripheral edema (21%), nausea (29%) and diarrhea (19.4%). Grade 3 or 4 adverse effects were observed in 6.5% of the patients. This real-life data confirms efficacy and safety of crizotinib in the treatment of advanced NSCLC harboring MET alteration.
  • Placeholder
    PublicationMetadata only
    Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
    (Elsevier, 2022) Nomak, G.; Oksuzoglu, B.; Senturk, R.; Eralp, Y.; Nomak, H.; Sanyal, R.; N/A; Orer, Hakan S.; Yumuk, Perran Fulden; Faculty Member; Other; School of Medicine; School of Medicine; 53477; N/A
    N/A
  • Placeholder
    PublicationMetadata only
    Age-adjusted Charlson comorbidity index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities
    (Elsevier Masson s.r.l., 2023) Akin Telli, Tugba; Can Demircan, Nazim; Sariyar, Nisanur; Arikan, Rukiye; Basoglu, Tugba; Yasar, Alper; Celebi, Abdussamet; Isik, Selver; Sofulu, Omer; Erol, Bulent; Turkoz, Huseyin Kemal; Ozgen, Zerrin; Ercelep, Ozlem; Dane, Faysal; N/A; Yumuk, Perran Fulden; Alan, Özkan; Other; Doctor; School of Medicine; N/A; Koç University Hospital; N/A; N/A
    Background: Advanced age and presence of comorbidities affect prognosis and treatment decisions in patients with soft tissue sarcoma (STS). However, coeffect of age and comorbidities is still unknown. We aimed to investigate prognostic value of age-adjusted Charlson Comorbidity Index (ACCI) in trunk and extremity STS operated with curative intent. Hypothesis: Preoperative ACCI might predict survival outcomes independently in patients with STS of trunk and extremities. Patients and Methods: The study included 151 patients and ACCI was calculated for each patient. We categorized the patients into two groups according to median ACCI. We retrospectively collected data about clinicopathologic and treatment-related factors, and evaluated potential prognostic factors for disease-free survival (DFS) and overall survival (OS) using univariate and multivariate analyses. Results: Median age was 50 (18–86) years. There were 89 male and 62 female patients. Lower extremities were the most common tumor sites (73.5%). Most of the patients had high grade tumors (84.1%) and stage 3 disease (66.9%). Radiotherapy and chemotherapy were carried out in 106 and 58 patients, respectively. Overall prevalence of comorbidity was 29.1%. Median ACCI was 3 (2-9). Older age (p < 0.001), worse performance status (p < 0.001), larger tumor size (p = 0.03), higher grade tumors (p = 0.03) and advanced stage (p = 0.04) were associated with higher ACCI (≥3). Median follow-up time was 32 months, 50.3% of patients had disease recurrence, and 35.8% died. Median DFS (p = 0.001) and OS (p = 0.001) of patients with low ACCI (< 3) were significantly longer than patients with high ACCI. Multivariate analysis determined ACCI as an independent prognostic indicator for both DFS (HR 1.72, p = 0.02) and OS (HR 2.02, p = 0.04). Discussion: ACCI is a valuable prognostic tool to be used in the preoperative setting of patients with STS. Higher ACCI was found to be independently associated with worse survival outcomes. For each patient with STS, evaluating comorbidities and combining them with age appears to be a critical step in modifying therapy options.
  • Placeholder
    PublicationMetadata only
    Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised imdc risk model by including 18F-FDG PET-CT parameters
    (Sage Publications Ltd) Arikan, Rukiye; Ozguven, Salih; Telli, Tugba Akin; Isik, Selver; Demircan, Nazim Can; Basoglu, Tugba; Yasar, Alper; Celebi, Abdussamet; Filizoglu, Nuh; Ustun, Hilal Sagiroglu; Tinay, Ilker; Ones, Tunc; Turoglu, Halil Turgut; Erdil, Tanju Yusuf; Ozturk, Mehmet Akif; Ercelep, Ozlem; Bayoglu, Vedat; Kostek, Osman; Dane, Faysal; N/A; Yumuk, Perran Fulden; Other; School of Medicine; N/A
    Background: Prognostic markers in metastatic renal cell cancer (mRCC) are still insufficient. Any prognostic model objectively determines disease burden. Purpose: To investigate the relationship between 18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters and outcomes in mRCC, and to define a revised International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for the intermediate-risk group. Material and Methods: A retrospective study of mRCC was conducted. To investigate the prognostic significance of 18F-FDG PET/CT parameters, maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), and metabolic tumor volume (MTV) were determined in pre-treatment images. Cutoff values were defined by ROC curve analyses and their association with outcomes was analyzed. Additionally, a TLG-adjusted IMDC model was created by stratifying intermediate-risk group patients according to TLG levels. Results: The study included 52 patients. The disease control rate (DCR) was 61.5% and median overall survival (OS) was 18 months (95% confidence interval=9.2–25.8). In the univariate analyses, IMDC score, MTV, and TLG were prognostic factors for Disease Control Rate (DCR), and Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS), IMDC score, lactate dehydrogenase (LDH), treatment option, MTV, and TLG were prognostic factors for OS (P < 0.05 each). In the multivariate analyses, MTV was an independent prognostic factor for DCR, and ECOG-PS, LDH, IMDC score, and TLG were independent prognostic factors for OS. According to the revised-IMDC model, the intermediate-favorable group showed longer OS than the intermediate-unfavorable group. Conclusion: Pretreatment MTV was independent prognostic factor for DCR and ECOG-PS, LDH, IMDC score, and TLG were independent prognostic factors for OS. Revised-IMDC model could identify patients with a worse prognosis among the IMDC intermediate-risk group.
  • Placeholder
    PublicationMetadata only
    Impact of skeletal muscle measurements by chest computed tomography on survival and postoperative complications in patients with soft tissue sarcoma
    (Routledge Journals, Taylor & Francis Ltd, 2022) Telli, Tugba Akin; Bugdayci, Onur; Alan, Ozkan; Sariyar, Nisanur; Isik, Selver; Arikan, Rukiye; Yasar, Alper; Majidova, Nargiz; Celebi, Abdussamet; Erol, Bulent; Ozgen, Zerrin; Kostek, Osman; Bayoglu, Ibrahim Vedat; Ercelep, Ozlem; Dane, Faysal; N/A; Yumuk, Perran Fulden; Other; School of Medicine; Koç University Hospital; N/A
    This study aims to evaluate whether sarcopenia, measured by chest computed tomography (CT), affects survival outcomes and postoperative complications in soft tissue sarcoma (STS) patients undergoing surgery. In this retrospective study, CT scans of 79 patients were reviewed to measure pectoralis and T12 vertebra muscle area. Both were then adjusted for height (cm(2)/m(2)) as pectoralis muscle index (PMI) and T12 vertebra muscle index (TMI). Analyses were performed by dichotomizing muscle indices at gender-specific 50th percentile; PMI and TMI < 50th percentile were defined as low, and >= 50th percentile as high. Overall postsurgical complication rate (PCR) was 16%. Median length of hospital stay (LOHS) was 10 days (3-90). PMI and TMI were significantly lower in women (p = 0.02, p = 0.04). Median body mass index was significantly higher in high PMI and TMI groups (p = 0.01 for both). PCR and LOHS were similar between low and high PMI and TMI groups. Median follow-up was 29 months, 37 patients had recurrence and 23 died. No significant difference was noted between low and high PMI and TMI groups, in terms of disease-free or overall survival. PMI and TMI as measured by chest CT had no impact on survival outcomes or postoperative complications in localized STS.
  • Placeholder
    PublicationMetadata only
    Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
    (Springer, 2022) Telli, Tugba Akin; Ozguven, Salih; Alan, Ozkan; Filizoglu, Nuh; Ozturk, Mehmet Akif; Sariyar, Nisanur; Isik, Selver; Arikan, Rukiye; Demircan, Nazim Can; Basoglu, Tugba; Cetin, Ilknur Alsan; Ones, Tunc; Ercelep, Ozlem; Dane, Faysal; N/A; Yumuk, Perran Fulden; Other; School of Medicine; Koç University Hospital; N/A
    Objective: We aimed to evaluate whether baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and Methods: This retrospective study included 54 mCRPC patients, who underwent baseline 68Ga-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of ≥ 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results: Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001–1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189–4.222, p = 0.01) as independent predictors of OS. Conclusion: The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.